Cognitive / Anxiolytic Peptide

Semax: Russian ACTH(4-10) Heptapeptide Nootropic

A UK-focused, evidence-based comparison of Semax and Dihexa — mechanism, benefits, dosing, side effects, legal status, and stacking.

Semax is a synthetic heptapeptide developed in the Soviet Union in the 1980s as an analogue of fragment 4-10 of adrenocorticotropic hormone (ACTH), with the proline tail added to dramatically extend its biological half-life. Sequence: Met-Glu-His-Phe-Pro-Gly-Pro. It is officially approved as a medicine in Russia and Ukraine for stroke (ischaemic), optic neuropathy, cognitive impairment and ADHD-like conditions, but holds no marketing authorisation from the MHRA, EMA or FDA. In the international nootropic community Semax is one of the most widely-used peptides alongside Selank and BPC-157, valued for its acute cognitive sharpening, sustained BDNF/NGF upregulation, and well-documented intranasal bioavailability.

What is Semax?

Semax (USAN: Semax) is a regulatory peptide derived from the N-terminal region of ACTH but with the C-terminal stripped of its steroidogenic activity. Adding the C-terminal "Pro-Gly-Pro" tail (sourced from Russian neurochemist Ashmarin's lab) confers resistance to peptidase degradation, allowing meaningful CNS penetration through the cribriform plate after intranasal administration. It is sold in Russia under the brand names Semax (0.1%) and Semax 1% (the higher-strength stroke formulation), and is listed on the Russian List of Vital and Essential Drugs. The compound has been the subject of more than 200 peer-reviewed papers, the majority from Russian institutions including the Institute of Molecular Genetics, Sechenov First Moscow State Medical University, and the Lomonosov MSU Faculty of Biology.

Chemistry: Met-Glu-His-Phe-Pro-Gly-Pro · MW 813.91 g/mol · ACTH(4-10) analogue
Origin: Institute of Molecular Genetics, Russian Academy of Sciences (developed 1980s)
Primary route: Intranasal spray (primary) · subcutaneous (rare)
Pharmacokinetics: Functional CNS half-life of minutes after intranasal dose, but BDNF/NGF upregulation persists for 24+ hours.
Class: Russian peptide · ACTH analogue

Mechanism of Action

Semax operates through multiple, partly-redundant CNS pathways which is why its effect profile feels broader than a typical single-receptor nootropic. The headline mechanism is sustained upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) mRNA in the hippocampus and basal forebrain (Dolotov et al., 2006; Shadrina et al., 2010), with measurable BDNF protein increases persisting more than 24 hours after a single 250 µg/kg intranasal dose in rodents despite Semax itself being cleared within minutes. A second pathway is melanocortin receptor activity — Semax retains affinity at MC4R and MC5R (without the cortisol-driving MC2R activity of full-length ACTH), modulating attention, arousal and inflammation. Additional effects include enhancement of central serotonergic and dopaminergic tone (Eremin et al., 2005), upregulation of the trophic peptide tuftsin, attenuation of pro-inflammatory cytokines (TNF-α, IL-1β) in microglia, and a documented anti-platelet / cerebroprotective action that underpins its Russian stroke indication. Unlike Dihexa, Semax does not directly activate HGF/c-Met and does not promote structural dendritic spine formation in the same way — it is a trophic-factor upregulator rather than a synaptogenic peptide.

Proposed Benefits

Anecdotal and small-trial reports converge on a fairly consistent benefit profile: improved focus and stamina on demanding cognitive tasks within 15-30 minutes of intranasal dosing, reduced mental fatigue across 6-8 hour work blocks, mild anxiolysis and emotional resilience without sedation, and cumulative improvements in memory and verbal fluency over 7-14 day courses. In Russian clinical practice Semax is used for: acute ischaemic stroke (where the 1% formulation reduces NIHSS scores and 30-day mortality in controlled trials), transient ischaemic attack, optic nerve atrophy and glaucomatous optic neuropathy, post-concussion syndrome, ADHD in children (a 14-day intranasal course), and cognitive impairment in elderly patients. The strongest preclinical signal sits with neuroprotection after ischaemia-reperfusion injury, where Semax reduces infarct volume by 30-50% in MCAO rat models. For healthy users seeking cognitive enhancement the realistic expectation is acute focus and stamina improvement on dosing days plus modest mood lift, rather than a structural rewrite of cognition.

Evidence Base

The published evidence base for Semax is substantial in volume but skewed Russian and short-duration. PubMed indexes more than 200 papers including: Kaplan et al. 2002 (BDNF/NGF expression in PC12 cells), Dolotov et al. 2006 (hippocampal BDNF upregulation in vivo), Eremin et al. 2005 (monoamine modulation), Medvedeva et al. 2014 (proteomic analysis of cortex after acute and chronic dosing), Asmarin et al. 1997 (the original stroke trial), Gusev et al. 2005 (Russian stroke registry, n=160). The Russian stroke Phase 3 data (Gusev, 2005) supports a 15-20% absolute reduction in 30-day mortality vs standard care, though by Western methodological standards the trial design is sub-optimal. Translational gaps: no Western Phase 3 trials, no head-to-head against modafinil or methylphenidate, no published study in healthy enhancement-seeking populations. The mechanism (BDNF/NGF upregulation, neuroprotection) is well established; the size-of-effect for healthy users is not formally quantified.

Dosage & Administration

No medically approved dose exists outside Russia/Ukraine. The Russian 0.1% formulation is dosed at 2-3 drops in each nostril, 2-3 times per day, for 7-14 days as a cognitive course (total ~250-1000 µg/day). The 1% stroke formulation goes higher (12-18 mg/day) under medical supervision. Community-reported nootropic protocols typically use the 0.1% spray or a research-grade reconstituted vial delivering 300-600 µg intranasally 1-2 times per day, cycled for 10-21 days on then 7+ days off. Bioavailability via the intranasal route is reported at 60-70% to brain tissue. Tilt head back, dose into each nostril without sniffing hard (the goal is mucosal absorption, not lung delivery). Subcutaneous injection is occasionally reported but offers no advantage and may increase peripheral side effects.

This is a community-reported protocol summary, not a medical recommendation. There is no established human dose. Consult a qualified healthcare professional before using any research compound.

Side Effects & Risks

Semax has a benign acute safety profile in published Russian literature and decades of clinical use, but data on long-term cognitive-enhancement-style dosing in healthy adults is essentially absent. Reported issues: mild nasal irritation or rhinitis (mostly from the saline vehicle, not the peptide), transient headache in the first 1-2 days, vivid dreams, occasional irritability or feeling "wired" with higher doses or in sensitive individuals, mild tachycardia in a minority. Because Semax interacts with the melanocortin system there is a theoretical concern about MC1R-driven skin pigmentation changes with prolonged use, though this has not been systematically studied in cosmetic populations. Contraindications: active psychotic illness (anecdotal reports of mania-like activation), pregnancy/breastfeeding (no safety data), known hypersensitivity. Semax appears safe in combination with most common medications but data is limited; caution with MAOIs and stimulants.

UK Legal Status

In the United Kingdom Semax is not a controlled substance under the Misuse of Drugs Act 1971, is not licensed as a medicine by the MHRA, and is not listed under the Psychoactive Substances Act 2016 (peptides modulating trophic factors do not meet the psychoactive substance definition). It is legal to purchase and possess as a research chemical for laboratory use; it cannot be lawfully sold for human consumption or for treatment of any condition. WADA does not list Semax on the Prohibited List as of the 2026 update, though athletes should check the current list. The compound is listed as a banned substance in Australia and is a controlled substance in the United States under the FDA's interpretation following the 2014 dietary supplement amendments.

Semax vs Dihexa

Semax and Dihexa occupy different but partially overlapping niches in the peptide nootropic landscape. Semax is a trophic-factor upregulator: it acutely raises BDNF and NGF expression, modulates monoamines, and provides intra-session focus/stamina via the melanocortin system. Its effects feel like a clean, sustained "task engagement" lift. Dihexa is a structural synaptogenic peptide: it activates the HGF/c-Met pathway, promoting new dendritic spine formation that outlasts the molecule's presence in plasma — effects accumulate over weeks. Semax is acutely useful, Dihexa is structurally cumulative. Route differs: Semax is intranasal (60-70% CNS bioavailability), Dihexa is orally bioavailable (~38%). Half-life logic is opposite: Semax molecule clears in minutes but trophic effects persist 24h; Dihexa has long structural impact via gene-expression changes that persist after the drug clears. Theoretically the two stack well — Semax for acute focus, Dihexa for structural reinforcement — though no formal interaction studies exist. Both share a credible BDNF-upstream mechanism, but only Dihexa is also a direct synaptogenic agent.

Stacking with Dihexa

Semax is one of the most commonly stacked peptides in the cognitive-enhancement community. With Dihexa the rationale is complementary: Semax delivers acute task-day focus and trophic factor upregulation; Dihexa delivers structural synaptogenic remodelling on the order of weeks. Other reported stacks include Semax + Selank (the classic Russian "Slavic stack" balancing focus and anxiolysis), Semax + modafinil for ultra-demanding cognitive work blocks, Semax + Lion's Mane mushroom for combined NGF / BDNF amplification, and Semax + L-tyrosine for catecholamine substrate support. There is no published interaction data between Semax and Dihexa specifically; the two have distinct primary receptors (melanocortin vs c-Met) and there is no mechanistic reason to expect competition. Avoid stacking with MAOIs due to monoamine modulation, and approach combinations with stimulants cautiously.

Frequently Asked Questions

They are not directly comparable on potency. Semax acts via trophic factor upregulation (BDNF/NGF) and melanocortin signalling; Dihexa acts through direct HGF/c-Met activation and structural synaptogenesis. Both have credible neuroplasticity-positive mechanisms but produce different subjective and structural effects.

No — oral bioavailability is essentially zero due to gastric peptidase degradation. The intranasal route uses olfactory and trigeminal pathways to bypass the blood-brain barrier and is the standard route for both clinical and nootropic use.

Yes, as a research chemical for laboratory use. It is not a controlled substance, not scheduled under the Psychoactive Substances Act, and not licensed as a medicine by the MHRA.

Acute effects (focus, stamina, mood lift) appear within 15-30 minutes of intranasal dosing. Cumulative BDNF/NGF upregulation builds over 7-14 days of consistent dosing.

Semax was not on the WADA Prohibited List as of the 2026 update, but athletes should confirm with the current list before competition. Several Russian peptides have been added in recent years.

The 1% formulation is the higher-strength stroke / acute neurological indication preparation used in Russian hospitals (12-18 mg/day). The 0.1% is the standard cognitive / mild indication formulation. Most research-chemical sources sell 30 mg or 60 mg lyophilised vials for reconstitution to the user’s chosen concentration.

The Bottom Line

Semax is one of the most validated nootropic peptides by Russian clinical standards, with a clean safety record, well-characterised intranasal pharmacokinetics, and a reproducible acute focus / stamina profile. It is mechanistically distinct from Dihexa — trophic-factor upregulation versus direct synaptogenesis — and the two are theoretically complementary rather than redundant. For healthy users seeking acute cognitive engagement and mood support across demanding work periods, Semax is the most evidence-supported peptide in this list after Cerebrolysin.